17.68
0.48 (2.79%)
| 前收盘价格 | 17.20 |
| 收盘价格 | 17.40 |
| 成交量 | 905,734 |
| 平均成交量 (3个月) | 1,489,170 |
| 市值 | 1,792,208,000 |
| 价格/销量 (P/S) | 16.59 |
| 股市价格/股市净资产 (P/B) | 4.58 |
| 52周波幅 | |
| 利润日期 | 28 Jan 2026 |
| 营业利益率 (TTM) | -340.67% |
| 稀释每股收益 (EPS TTM) | -2.60 |
| 季度收入增长率 (YOY) | 11.30% |
| 总债务/股东权益 (D/E MRQ) | 5.54% |
| 流动比率 (MRQ) | 6.26 |
| 营业现金流 (OCF TTM) | -191.72 M |
| 杠杆自由现金流 (LFCF TTM) | -106.56 M |
| 资产报酬率 (ROA TTM) | -31.08% |
| 股东权益报酬率 (ROE TTM) | -64.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Nurix Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.20 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.41% |
| 机构持股比例 | 111.85% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 32.00 (Piper Sandler, 81.00%) | 购买 |
| 中 | 27.00 (52.72%) | |
| 低 | 15.00 (Morgan Stanley, -15.16%) | 保留 |
| 平均值 | 25.67 (45.19%) | |
| 总计 | 8 购买, 1 保留 | |
| 平均价格@调整类型 | 11.46 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 30.00 (69.68%) | 购买 | 17.15 |
| BTIG | 04 Nov 2025 | 27.00 (52.71%) | 购买 | 12.26 |
| 23 Oct 2025 | 27.00 (52.71%) | 购买 | 10.40 | |
| Needham | 04 Nov 2025 | 26.00 (47.06%) | 购买 | 12.26 |
| 22 Oct 2025 | 26.00 (47.06%) | 购买 | 10.63 | |
| HC Wainwright & Co. | 27 Oct 2025 | 28.00 (58.37%) | 购买 | 11.98 |
| 20 Oct 2025 | 33.00 (86.65%) | 购买 | 10.39 | |
| Wells Fargo | 23 Oct 2025 | 21.00 (18.78%) | 购买 | 10.40 |
| Mizuho | 21 Oct 2025 | 24.00 (35.75%) | 购买 | 10.42 |
| Morgan Stanley | 14 Oct 2025 | 15.00 (-15.16%) | 保留 | 9.18 |
| Oppenheimer | 10 Oct 2025 | 28.00 (58.37%) | 购买 | 9.76 |
| Piper Sandler | 10 Oct 2025 | 32.00 (81.00%) | 购买 | 9.76 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 17.15 | -37,600 | -644,840 |
| 累积净数量 | -37,600 | |||
| 累积净值 ($) | -644,840 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 17.15 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | 职员 | 24 Nov 2025 | 自动卖出 (-) | 37,600 | 17.15 | 644,840 |
| RING CHRISTINE | 职员 | 24 Nov 2025 | 执行期权 | 37,600 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合